Chemomab Therapeutics LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Chemomab Therapeutics Ltd. shareholders, including HBM Healthcare Investments, have entered into a support agreement to vote in favor of the proposed merger with Scipher Medicine Corporation.
NASDAQ
OrbiMed Israel BioFund GP Limited Partnership and its affiliates have filed an exit Schedule 13D/A, reporting a reduction in their beneficial ownership of Chemomab Therapeutics Ltd. to below 5% following a sale of 1.61 million ADSs.